News

Medigene achieves positive preliminary results in Phase I of Phase I/II trial of TCR-T therapy MDG1011 in blood cancers

SHOW RELEASE

New safety data shows Medigene's inducible system produces correctly-paired T cell receptors only

SHOW RELEASE

Medigene, IRICoR, and University of Montréal expand analyses of potentially novel cancer antigens

SHOW RELEASE

Medigene provides Q3 2021 update

SHOW RELEASE

Data validating TCR-Ts targeted to ovarian tumor-specific "dark matter" antigen to be presented at SITC

SHOW RELEASE

Medigene participates at upcoming conferences

SHOW RELEASE

Medigene receives USD2 m milestone payment from Roivant/Cytovant and improves financial forecast for 2021

SHOW RELEASE

Neoantigens shared amongst patients and indications broaden the applicability of T cell-based cancer immunotherapies

SHOW RELEASE

Medigene's PD1-41BB switch receptor improves TCR-T cell functionality against solid tumors

SHOW RELEASE

Medigene extends cash reach into the first quarter of 2023

SHOW RELEASE

Medigene provides Q2 update and 6M report 2020

SHOW RELEASE

Medigene participates at upcoming conferences

SHOW RELEASE

Medigene reports on Annual General Meeting 2021

SHOW RELEASE

Medigene presents compelling in vivo data for use of PD1-41BB-enhanced TCR-T cells against solid tumors

SHOW RELEASE

Medigene provides Q1 2021 update

SHOW RELEASE